2024

Deciphering the impact of genomic variation on function.
IGVF Consortium. Nature. 2024 Sep;633(8028):47-57. doi: 10.1038/s41586-024-07510-0. Epub 2024 Sep 4.

Epigenome editing technologies for discovery and medicine.
McCutcheon SR, Rohm D, Iglesia N, Gersbach CA. Nat Biotechnol. 2024 July. https://doi.org/10.1038/s41587-024-02320-1

Respiratory characterization of a humanized Duchenne muscular dystrophy mouse model.
Roger AL, Biswas DD, Huston ML, Le D, Bailey AM, Pucci LA, Shi Y, Robinson-Hamm J, Gersbach CA, ElMallah MK. Respir Physiol Neurobiol. 2024 Aug;326:104282. doi: 10.1016/j.resp.2024.104282. Epub 2024 May 21.PMID: 38782084

Machine learning methods for predicting guide RNA effects in CRISPR epigenome editing experiments.
Mu W, Luo T, Barrera A, Bounds LR, Klann TS, ter Weele M, Bryois J, Crawford GE, Sullivan PF, Gersbach CA, Love MI, Li Y. bioRxiv 2024.04.18.590188; doi: https://doi.org/10.1101/2024.04.18.590188

Multicenter integrated analysis of noncoding CRISPRi screens.
Yao D, Tycko J, Oh JW, Bounds LR, Gosai SJ, Lataniotis L, Mackay-Smith A, Doughty BR, Gabdank I, Schmidt H, Guerrero-Altamirano T, Siklenka K, Guo K, White AD, Youngworth I, Andreeva K, Ren X, Barrera A, Luo Y, Yardımcı GG, Tewhey R, Kundaje A, Greenleaf WJ, Sabeti PC, Leslie C, Pritykin Y, Moore JE, Beer MA, Gersbach CA, Reddy TE, Shen Y, Engreitz JM, Bassik MC, Reilly SK. Nat Methods. 2024 Apr;21(4):723-734. doi: 10.1038/s41592-024-02216-7. Epub 2024 Mar 19.PMID: 38504114

Activation of the imprinted Prader-Willi Syndrome locus by CRISPR-based epigenome editing.
Rohm D, Black JB, McCutcheon SR, Barrera A, Morone DJ, Nuttle X, de Esch CE, Tai DJC, Talkowski ME, Iglesias N, Gersbach CA. bioRxiv 2024.03.03.583177; doi: https://doi.org/10.1101/2024.03.03.583177

A humanized mouse model for adeno-associated viral gene therapy.
Barzi M, Chen T, Gonzalez TJ, Pankowicz FP, Oh SH, Streff HL, Rosales A, Ma Y, Collias S, Woodfield SE, Diehl AM, Vasudevan SA, Galvan TN, Goss J, Gersbach CA, Bissig-Choisat B, Asokan A, Bissig KD. Nat Commun. 2024 Mar 4;15(1):1955. doi: 10.1038/s41467-024-46017-0.PMID: 38438373

Mechanosensitive genomic enhancers potentiate the cellular response to matrix stiffness.
Cosgrove BD, Bounds LR, Key Taylor C, Su AL, Rizzo AJ, Barrera A, Crawford GE, Hoffman BD, Gersbach CA. bioRxiv 2024.01.10.574997; doi: https://doi.org/10.1101/2024.01.10.574997

2023

Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens.
McCutcheon SR, Swartz AM, Brown MC, Barrera A, McRoberts Amador C, Siklenka K, Humayun L, Ter Weele MA, Isaacs JM, Reddy TE, Allen AS, Nair SK, Antonia SJ, Gersbach CA. Nat Genet. 2023 Dec;55(12):2211-2223. doi: 10.1038/s41588-023-01554-0. Epub 2023 Nov 9.PMID: 37945901 

PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system.
Lee JH, Shores KL, Breithaupt JJ, Lee CS, Fodera DM, Kwon JB, Ettyreddy AR, Myers KM, Evison BJ, Suchowerska AK, Gersbach CA, Leong KW, Truskey GA. APL Bioeng. 2023 Oct 16;7(4):046103. doi: 10.1063/5.0167440. eCollection 2023 Dec.PMID: 37854060 

Nonviral In Vivo Delivery of CRISPR-Cas9 Using Protein-Agnostic, High-Loading Porous Silicon and Polymer Nanoparticles.
Fletcher RB, Stokes LD, Kelly IB 3rd, Henderson KM, Vallecillo-Viejo IC, Colazo JM, Wong BV, Yu F, d'Arcy R, Struthers MN, Evans BC, Ayers J, Castanon M, Weirich MJ, Reilly SK, Patel SS, Ivanova YI, Silvera Batista CA, Weiss SM, Gersbach CA, Brunger JM, Duvall. CL.ACS Nano. 2023 Sep 12;17(17):16412-16431. doi: 10.1021/acsnano.2c12261. Epub 2023 Aug 15.PMID: 37582231

Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell function.
McCutcheon SR, Swartz AM, Brown MC, Barrera A, Amador CM, Siklenka K, Humayun L, Isaacs JM, Reddy TE, Nair S, Antonia S, Gersbach CA. bioRxiv. 2023 May 1:2023.05.01.538906. doi: 10.1101/2023.05.01.538906. Preprint.PMID: 37205457 

An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair.
Yan R, Cigliola V, Oonk KA, Petrover Z, DeLuca S, Wolfson DW, Vekstein A, Mendiola MA, Devlin G, Bishawi M, Gemberling MP, Sinha T, Sargent MA, York AJ, Shakked A, DeBenedittis P, Wendell DC, Ou J, Kang J, Goldman JA, Baht GS, Karra R, Williams AR, Bowles DE, Asokan A, Tzahor E, Gersbach CA, Molkentin JD, Bursac N, Black BL, Poss KD. Cell Stem Cell. 2023 Jan 5;30(1):96-111.e6. doi: 10.1016/j.stem.2022.11.012. Epub 2022 Dec 13.PMID: 36516837 

2022

Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing.
Gonzalez TJ, Simon KE, Blondel LO, Fanous MM, Roger AL, Maysonet MS, Devlin GW, Smith TJ, Oh DK, Havlik LP, Castellanos Rivera RM, Piedrahita JA, ElMallah MK, Gersbach CA, Asokan A. Nat Commun. 2022 Oct 10;13(1):5947. doi: 10.1038/s41467-022-33745-4.PMID: 36210364 

Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators.
Beyersdorf JP, Bawage S, Iglesias N, Peck HE, Hobbs RA, Wroe JA, Zurla C, Gersbach CA, Santangelo PJ. ACS Nano. 2022 Apr 26;16(4):5660-5671. doi: 10.1021/acsnano.1c10631. Epub 2022 Mar 31.PMID: 35357116 

2021

Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.
Hakim CH, Kumar SRP, Pérez-López DO, Wasala NB, Zhang D, Yue Y, Teixeira J, Pan X, Zhang K, Million ED, Nelson CE, Metzger S, Han J, Louderman JA, Schmidt F, Feng F, Grimm D, Smith BF, Yao G, Yang NN, Gersbach CA, Chen SJ, Herzog RW, Duan D. Nat Commun. 2021 Nov 24;12(1):6769. doi: 10.1038/s41467-021-26830-7.PMID: 34819506 

Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
Pickar-Oliver A, Gough V, Bohning JD, Liu S, Robinson-Hamm JN, Daniels H, Majoros WH, Devlin G, Asokan A, Gersbach CA. Mol Ther. 2021 Nov 3;29(11):3243-3257. doi: 10.1016/j.ymthe.2021.09.003. Epub 2021 Sep 10.PMID: 34509668 

Transgenic mice for in vivo epigenome editing with CRISPR-based systems.
Gemberling MP, Siklenka K, Rodriguez E, Tonn-Eisinger KR, Barrera A, Liu F, Kantor A, Li L, Cigliola V, Hazlett MF, Williams CA, Bartelt LC, Madigan VJ, Bodle JC, Daniels H, Rouse DC, Hilton IB, Asokan A, Ciofani M, Poss KD, Reddy TE, West AE, Gersbach CA. Nat Methods. 2021 Aug;18(8):965-974. doi: 10.1038/s41592-021-01207-2. Epub 2021 Aug 2.PMID: 34341582 

Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science.
Abdeen AA, Cosgrove BD, Gersbach CA, Saha K. Annu Rev Biomed Eng. 2021 Jul 13;23:493-516. doi: 10.1146/annurev-bioeng-122019-121602. Epub 2021 Apr 28.PMID: 33909475 

CRISPR Clocks: The Times They Are a-Changin'.
Bodle JC, Gersbach CA. CRISPR J. 2021 Apr;4(2):160-163. doi: 10.1089/crispr.2021.29123.ger.PMID: 33876949 

The NIH Somatic Cell Genome Editing program.
Saha K, Sontheimer EJ, Brooks PJ, Dwinell MR, Gersbach CA, Liu DR, Murray SA, Tsai SQ, Wilson RC, Anderson DG, Asokan A, Banfield JF, Bankiewicz KS, Bao G, Bulte JWM, Bursac N, Campbell JM, Carlson DF, Chaikof EL, Chen ZY, Cheng RH, Clark KJ, Curiel DT, Dahlman JE, Deverman BE, Dickinson ME, Doudna JA, Ekker SC, Emborg ME, Feng G, Freedman BS, Gamm DM, Gao G, Ghiran IC, Glazer PM, Gong S, Heaney JD, Hennebold JD, Hinson JT, Khvorova A, Kiani S, Lagor WR, Lam KS, Leong KW, Levine JE, Lewis JA, Lutz CM, Ly DH, Maragh S, McCray PB Jr, McDevitt TC, Mirochnitchenko O, Morizane R, Murthy N, Prather RS, Ronald JA, Roy S, Roy S, Sabbisetti V, Saltzman WM, Santangelo PJ, Segal DJ, Shimoyama M, Skala MC, Tarantal AF, Tilton JC, Truskey GA, Vandsburger M, Watts JK, Wells KD, Wolfe SA, Xu Q, Xue W, Yi G, Zhou J; SCGE Consortium. Nature. 2021 Apr;592(7853):195-204. doi: 10.1038/s41586-021-03191-1. Epub 2021 Apr 7.PMID: 33828315 

Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart.
Walejko JM, Christopher BA, Crown SB, Zhang GF, Pickar-Oliver A, Yoneshiro T, Foster MW, Page S, van Vliet S, Ilkayeva O, Muehlbauer MJ, Carson MW, Brozinick JT, Hammond CD, Gimeno RE, Moseley MA, Kajimura S, Gersbach CA, Newgard CB, White PJ, McGarrah RW. Nat Commun. 2021 Mar 15;12(1):1680. doi: 10.1038/s41467-021-21962-2.PMID: 33723250 

AP-1 subunits converge promiscuously at enhancers to potentiate transcription.
Seo J, Koçak DD, Bartelt LC, Williams CA, Barrera A, Gersbach CA, Reddy TE. Genome Res. 2021 Apr;31(4):538-550. doi: 10.1101/gr.267898.120. Epub 2021 Mar 5.PMID: 33674350 

2020

Master Regulators and Cofactors of Human Neuronal Cell Fate Specification Identified by CRISPR Gene Activation Screens.
Black JB, McCutcheon SR, Dube S, Barrera A, Klann TS, Rice GA, Adkar SS, Soderling SH, Reddy TE, Gersbach CA. Cell Rep. 2020 Dec 1;33(9):108460. doi: 10.1016/j.celrep.2020.108460.PMID: 33264623 

The once and future gene therapy.
Bulaklak K, Gersbach CA. Nat Commun. 2020 Nov 16;11(1):5820. doi: 10.1038/s41467-020-19505-2.PMID: 33199717 

Redirecting Vesicular Transport to Improve Nonviral Delivery of Molecular Cargo.
Mao M, Chang CC, Pickar-Oliver A, Cervia LD, Wang L, Ji J, Liton PB, Gersbach CA, Yuan F. Adv Biosyst. 2020 Aug;4(8):e2000059. doi: 10.1002/adbi.202000059. Epub 2020 Jul 21.PMID: 33179869 

In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy.
Kwon JB, Ettyreddy AR, Vankara A, Bohning JD, Devlin G, Hauschka SD, Asokan A, Gersbach CA. Mol Ther Methods Clin Dev. 2020 Sep 28;19:320-329. doi: 10.1016/j.omtm.2020.09.016. eCollection 2020 Dec 11.PMID: 33145368 

Enhancer RNAs predict enhancer-gene regulatory links and are critical for enhancer function in neuronal systems.
Carullo NVN, Phillips Iii RA, Simon RC, Soto SAR, Hinds JE, Salisbury AJ, Revanna JS, Bunner KD, Ianov L, Sultan FA, Savell KE, Gersbach CA, Day JJ. Nucleic Acids Res. 2020 Sep 25;48(17):9550-9570. doi: 10.1093/nar/gkaa671.PMID: 32810208 

Unwinding the Role of FACT in Cas9-based Genome Editing.
Cosgrove BD, Gersbach CA. Mol Cell. 2020 Aug 6;79(3):365-367. doi: 10.1016/j.molcel.2020.07.016.PMID: 32763224 

Immunity to Cas9 as an Obstacle to Persistent Genome Editing.
Gough V, Gersbach CA. Mol Ther. 2020 Jun 3;28(6):1389-1391. doi: 10.1016/j.ymthe.2020.05.007. Epub 2020 May 18.PMID: 32428441 

Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators.
Kwon JB, Vankara A, Ettyreddy AR, Bohning JD, Gersbach CA. Stem Cell Reports. 2020 May 12;14(5):755-769. doi: 10.1016/j.stemcr.2020.03.026. Epub 2020 Apr 23.PMID: 32330446 

Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter.
Dicks A, Wu CL, Steward N, Adkar SS, Gersbach CA, Guilak F. Stem Cell Res Ther. 2020 Feb 18;11(1):66. doi: 10.1186/s13287-020-01597-8.PMID: 32070421 

2019

Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous KrasG12D.
Huang J, Chen M, Xu ES, Luo L, Ma Y, Huang W, Floyd W, Klann TS, Kim SY, Gersbach CA, Cardona DM, Kirsch DG. Sci Rep. 2019 Nov 20;9(1):17220. doi: 10.1038/s41598-019-53572-w.PMID: 31748650 

An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles.
Evans BC, Fletcher RB, Kilchrist KV, Dailing EA, Mukalel AJ, Colazo JM, Oliver M, Cheung-Flynn J, Brophy CM, Tierney JW, Isenberg JS, Hankenson KD, Ghimire K, Lander C, Gersbach CA, Duvall CL. Nat Commun. 2019 Nov 1;10(1):5012. doi: 10.1038/s41467-019-12906-y.PMID: 31676764 

Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells.
Pickar-Oliver A, Black JB, Lewis MM, Mutchnick KJ, Klann TS, Gilcrest KA, Sitton MJ, Nelson CE, Barrera A, Bartelt LC, Reddy TE, Beisel CL, Barrangou R, Gersbach CA. Nat Biotechnol. 2019 Dec;37(12):1493-1501. doi: 10.1038/s41587-019-0235-7. Epub 2019 Sep 23.PMID: 31548729 

Jumping at the chance for precise DNA integration.
Kwon JB, Gersbach CA. Nat Biotechnol. 2019 Sep;37(9):1004-1006. doi: 10.1038/s41587-019-0210-3.PMID: 31371821 

AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice.
Nance ME, Shi R, Hakim CH, Wasala NB, Yue Y, Pan X, Zhang T, Robinson CA, Duan SX, Yao G, Yang NN, Chen SJ, Wagner KR, Gersbach CA, Duan D. Mol Ther. 2019 Sep 4;27(9):1568-1585. doi: 10.1016/j.ymthe.2019.06.012. Epub 2019 Jul 3.PMID: 31327755 

The next generation of CRISPR-Cas technologies and applications.
Pickar-Oliver A, Gersbach CA. Nat Rev Mol Cell Biol. 2019 Aug;20(8):490-507. doi: 10.1038/s41580-019-0131-5.PMID: 31147612 

Increasing the specificity of CRISPR systems with engineered RNA secondary structures.
Kocak DD, Josephs EA, Bhandarkar V, Adkar SS, Kwon JB, Gersbach CA. Nat Biotechnol. 2019 Jun;37(6):657-666. doi: 10.1038/s41587-019-0095-1. Epub 2019 Apr 15.PMID: 30988504 

Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, Robinson-Hamm JN, Bulaklak K, Castellanos Rivera RM, Collier JH, Asokan A, Gersbach CA. Nat Med. 2019 Mar;25(3):427-432. doi: 10.1038/s41591-019-0344-3. Epub 2019 Feb 18.PMID: 30778238 

Enhancer Histone Acetylation Modulates Transcriptional Bursting Dynamics of Neuronal Activity-Inducible Genes.
Chen LF, Lin YT, Gallegos DA, Hazlett MF, Gómez-Schiavon M, Yang MG, Kalmeta B, Zhou AS, Holtzman L, Gersbach CA, Grandl J, Buchler NE, West AE. Cell Rep. 2019 Jan 29;26(5):1174-1188.e5. doi: 10.1016/j.celrep.2019.01.032.PMID: 30699347 

Step-Wise Chondrogenesis of Human Induced Pluripotent Stem Cells and Purification Via a Reporter Allele Generated by CRISPR-Cas9 Genome Editing.
Adkar SS, Wu CL, Willard VP, Dicks A, Ettyreddy A, Steward N, Bhutani N, Gersbach CA, Guilak F. Stem Cells. 2019 Jan;37(1):65-76. doi: 10.1002/stem.2931. Epub 2018 Oct 31.PMID: 30378731 

2018

AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.
Hakim CH, Wasala NB, Nelson CE, Wasala LP, Yue Y, Louderman JA, Lessa TB, Dai A, Zhang K, Jenkins GJ, Nance ME, Pan X, Kodippili K, Yang NN, Chen SJ, Gersbach CA, Duan D. JCI Insight. 2018 Dec 6;3(23):e124297. doi: 10.1172/jci.insight.124297.PMID: 30518686 

Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding.
McDowell IC, Barrera A, D'Ippolito AM, Vockley CM, Hong LK, Leichter SM, Bartelt LC, Majoros WH, Song L, Safi A, Koçak DD, Gersbach CA, Hartemink AJ, Crawford GE, Engelhardt BE, Reddy TE. Genome Res. 2018 Sep;28(9):1272-1284. doi: 10.1101/gr.233346.117. Epub 2018 Aug 10.PMID: 30097539 

Pre-established Chromatin Interactions Mediate the Genomic Response to Glucocorticoids.
D'Ippolito AM, McDowell IC, Barrera A, Hong LK, Leichter SM, Bartelt LC, Vockley CM, Majoros WH, Safi A, Song L, Gersbach CA, Crawford GE, Reddy TE. Cell Syst. 2018 Aug 22;7(2):146-160.e7. doi: 10.1016/j.cels.2018.06.007. Epub 2018 Jul 18.PMID: 30031775 

Editing the Epigenome: Reshaping the Genomic Landscape.
Holtzman L, Gersbach CA. Annu Rev Genomics Hum Genet. 2018 Aug 31;19:43-71. doi: 10.1146/annurev-genom-083117-021632. Epub 2018 May 31.PMID: 29852072 Review.

Synthetic transcription factors for cell fate reprogramming.
Black JB, Gersbach CA. Curr Opin Genet Dev. 2018 Oct;52:13-21. doi: 10.1016/j.gde.2018.05.001. Epub 2018 May 24.PMID: 29803990 Review.

Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3D Woven Scaffolds.
Huynh NPT, Brunger JM, Gloss CC, Moutos FT, Gersbach CA, Guilak F. Tissue Eng Part A. 2018 Oct;24(19-20):1531-1544. doi: 10.1089/ten.TEA.2017.0510. Epub 2018 Jul 13.PMID: 29756533 

From CRISPR scissors to virus sensors.
Kocak DD, Gersbach CA. Nature. 2018 May;557(7704):168-169. doi: 10.1038/d41586-018-04975-8.PMID: 29730672 

RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors.
Thakore PI, Kwon JB, Nelson CE, Rouse DC, Gemberling MP, Oliver ML, Gersbach CA. Nat Commun. 2018 Apr 26;9(1):1674. doi: 10.1038/s41467-018-04048-4.PMID: 29700298 

Pulling the genome in opposite directions to dissect gene networks.
Gersbach CA, Barrangou R. Genome Biol. 2018 Mar 26;19(1):42. doi: 10.1186/s13059-018-1425-1.PMID: 29580291 

Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing.
Klann TS, Crawford GE, Reddy TE, Gersbach CA. Methods Mol Biol. 2018;1767:447-480. doi: 10.1007/978-1-4939-7774-1_25.PMID: 29524151

CRISPR-based methods for high-throughput annotation of regulatory DNA.
Klann TS, Black JB, Gersbach CA. Curr Opin Biotechnol. 2018 Aug;52:32-41. doi: 10.1016/j.copbio.2018.02.004. Epub 2018 Feb 28.PMID: 29500989 

Gene therapies for hemophilia hit the mark in clinical trials.
Pickar AK, Gersbach CA. Nat Med. 2018 Feb 7;24(2):121-122. doi: 10.1038/nm.4492.PMID: 29414930 

Boosting, Not Breaking: CRISPR Activators Treat Disease Models.
Gemberling M, Gersbach CA. Mol Ther. 2018 Feb 7;26(2):334-336. doi: 10.1016/j.ymthe.2018.01.004. Epub 2018 Feb 1.PMID: 29396264 

2017

Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies.
Manandhar D, Song L, Kabadi A, Kwon JB, Edsall LE, Ehrlich M, Tsumagari K, Gersbach CA, Crawford GE, Gordân R. Nucleic Acids Res. 2017 Nov 16;45(20):11684-11699. doi: 10.1093/nar/gkx773.PMID: 28977539 

Genome engineering: a new approach to gene therapy for neuromuscular disorders.
Nelson CE, Robinson-Hamm JN, Gersbach CA. Nat Rev Neurol. 2017 Nov;13(11):647-661. doi: 10.1038/nrneurol.2017.126. Epub 2017 Sep 29.PMID: 28960187 Review.

Genome Engineering for Personalized Arthritis Therapeutics.
Adkar SS, Brunger JM, Willard VP, Wu CL, Gersbach CA, Guilak F. Trends Mol Med. 2017 Oct;23(10):917-931. doi: 10.1016/j.molmed.2017.08.002. Epub 2017 Sep 5.PMID: 28887050 

An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis.
Polstein LR, Juhas M, Hanna G, Bursac N, Gersbach CA. ACS Synth Biol. 2017 Nov 17;6(11):2003-2013. doi: 10.1021/acssynbio.7b00147. Epub 2017 Sep 6.PMID: 28793186 

Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.
Huang J, Chen M, Whitley MJ, Kuo HC, Xu ES, Walens A, Mowery YM, Van Mater D, Eward WC, Cardona DM, Luo L, Ma Y, Lopez OM, Nelson CE, Robinson-Hamm JN, Reddy A, Dave SS, Gersbach CA, Dodd RD, Kirsch DG. Nat Commun. 2017 Jul 10;8:15999. doi: 10.1038/ncomms15999.PMID: 28691711 

Mammalian Synthetic Biology: Engineering Biological Systems.
Black JB, Perez-Pinera P, Gersbach CA. Annu Rev Biomed Eng. 2017 Jun 21;19:249-277. doi: 10.1146/annurev-bioeng-071516-044649.PMID: 28633563 Review.

Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs.
Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. Stem Cell Reports. 2017 May 9;8(5):1202-1213. doi: 10.1016/j.stemcr.2017.03.022. Epub 2017 Apr 27.PMID: 28457885 

Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2.
Pathak GP, Spiltoir JI, Höglund C, Polstein LR, Heine-Koskinen S, Gersbach CA, Rossi J, Tucker CL. Nucleic Acids Res. 2017 Nov 16;45(20):e167. doi: 10.1093/nar/gkx260.PMID: 28431041 

CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA. Nat Biotechnol. 2017 Jun;35(6):561-568. doi: 10.1038/nbt.3853. Epub 2017 Apr 3.PMID: 28369033 

Expanding the CRISPR Toolbox: Targeting RNA with Cas13b.
Barrangou R, Gersbach CA. Mol Cell. 2017 Feb 16;65(4):582-584. doi: 10.1016/j.molcel.2017.02.002.PMID: 28212745 

* CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments.
Farhang N, Brunger JM, Stover JD, Thakore PI, Lawrence B, Guilak F, Gersbach CA, Setton LA, Bowles RD. Tissue Eng Part A. 2017 Aug;23(15-16):738-749. doi: 10.1089/ten.TEA.2016.0441. Epub 2017 Feb 28.PMID: 28095751 

Genetic engineering: Chemical control for CRISPR editing.
Hilton IB, Gersbach CA. Nat Chem Biol. 2017 Jan;13(1):2-3. doi: 10.1038/nchembio.2243. Epub 2016 Nov 7.PMID: 27820804 No abstract available.

CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues.
Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. Arthritis Rheumatol. 2017 May;69(5):1111-1121. doi: 10.1002/art.39982. Epub 2017 Mar 31.PMID: 27813286

Loss-of-function genetic tools for animal models: cross-species and cross-platform differences.
Housden BE, Muhar M, Gemberling M, Gersbach CA, Stainier DY, Seydoux G, Mohr SE, Zuber J, Perrimon N. Nat Rev Genet. 2017 Jan;18(1):24-40. doi: 10.1038/nrg.2016.118. Epub 2016 Oct 31.PMID: 27795562 

2016

Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts.
Lee J, Xu L, Gibson TM, Gersbach CA, Sullenger BA. Biochem Biophys Res Commun. 2016 Sep 23;478(3):1484-90. doi: 10.1016/j.bbrc.2016.08.159. Epub 2016 Aug 29.PMID: 27586271 

Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.
Robinson-Hamm JN, Gersbach CA. Hum Genet. 2016 Sep;135(9):1029-40. doi: 10.1007/s00439-016-1725-z. Epub 2016 Aug 20.PMID: 27542949 

Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells.
Black JB, Adler AF, Wang HG, D'Ippolito AM, Hutchinson HA, Reddy TE, Pitt GS, Leong KW, Gersbach CA. Cell Stem Cell. 2016 Sep 1;19(3):406-14. doi: 10.1016/j.stem.2016.07.001. Epub 2016 Aug 11.PMID: 27524438 

Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing.
Moutos FT, Glass KA, Compton SA, Ross AK, Gersbach CA, Guilak F, Estes BT. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4513-22. doi: 10.1073/pnas.1601639113. Epub 2016 Jul 18.PMID: 27432980 

N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions.
Hwang PY, Jing L, Chen J, Lim FL, Tang R, Choi H, Cheung KM, Risbud MV, Gersbach CA, Guilak F, Leung VY, Setton LA. Sci Rep. 2016 Jun 13;6:28038. doi: 10.1038/srep28038.PMID: 27292569 

Engineering Delivery Vehicles for Genome Editing.
Nelson CE, Gersbach CA. Annu Rev Chem Biomol Eng. 2016 Jun 7;7:637-62. doi: 10.1146/annurev-chembioeng-080615-034711. Epub 2016 Apr 21.PMID: 27146557 Review.

Cas9 loosens its grip on off-target sites.
Nelson CE, Gersbach CA. Nat Biotechnol. 2016 Mar;34(3):298-9. doi: 10.1038/nbt.3501.PMID: 26963555 No abstract available.

In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
Landau DJ, Brooks ED, Perez-Pinera P, Amarasekara H, Mefferd A, Li S, Bird A, Gersbach CA, Koeberl DD. Mol Ther. 2016 Apr;24(4):697-706. doi: 10.1038/mt.2016.35. Epub 2016 Feb 11.PMID: 26865405 

Editing the epigenome: technologies for programmable transcription and epigenetic modulation.
Thakore PI, Black JB, Hilton IB, Gersbach CA. Nat Methods. 2016 Feb;13(2):127-37. doi: 10.1038/nmeth.3733.PMID: 26820547 

Genome-editing Technologies for Gene and Cell Therapy.
Maeder ML, Gersbach CA. Mol Ther. 2016 Mar;24(3):430-46. doi: 10.1038/mt.2016.10. Epub 2016 Jan 12.PMID: 26755333 

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. Science. 2016 Jan 22;351(6271):403-7. doi: 10.1126/science.aad5143. Epub 2015 Dec 31.PMID: 26721684 

Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage.
Josephs EA, Kocak DD, Fitzgibbon CJ, McMenemy J, Gersbach CA, Marszalek PE. Nucleic Acids Res. 2016 Mar 18;44(5):2474. doi: 10.1093/nar/gkv1293. Epub 2015 Nov 17.PMID: 26578578 

Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors.
Thakore PI, Gersbach CA. Methods Mol Biol. 2016;1338:71-88. doi: 10.1007/978-1-4939-2932-0_7.PMID: 26443215 

The Development of TALE Nucleases for Biotechnology.
Ousterout DG, Gersbach CA. Methods Mol Biol. 2016;1338:27-42. doi: 10.1007/978-1-4939-2932-0_3.PMID: 26443211 

2015

Genome editing: the end of the beginning.
Doudna JA, Gersbach CA. Genome Biol. 2015 Dec 23;16:292. doi: 10.1186/s13059-015-0860-5.PMID: 26700220 

Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Nat Methods. 2015 Dec;12(12):1143-9. doi: 10.1038/nmeth.3630. Epub 2015 Oct 26.PMID: 26501517

Enabling functional genomics with genome engineering.
Hilton IB, Gersbach CA. Genome Res. 2015 Oct;25(10):1442-55. doi: 10.1101/gr.190124.115.PMID: 26430154 

Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage.
Josephs EA, Kocak DD, Fitzgibbon CJ, McMenemy J, Gersbach CA, Marszalek PE. Nucleic Acids Res. 2015 Oct 15;43(18):8924-41. doi: 10.1093/nar/gkv892. Epub 2015 Sep 17.PMID: 26384421 

Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators.
Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L, Safi A, Crawford GE, Reddy TE, Gersbach CA. Genome Res. 2015 Aug;25(8):1158-69. doi: 10.1101/gr.179044.114. Epub 2015 May 29.PMID: 26025803 

Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment.
Gibson TM, Gersbach CA. Integr Biol (Camb). 2015 Jun;7(6):663-71. doi: 10.1039/c5ib00057b. Epub 2015 May 8.PMID: 25953198 

Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum.
Frank CL, Liu F, Wijayatunge R, Song L, Biegler MT, Yang MG, Vockley CM, Safi A, Gersbach CA, Crawford GE, West AE. Nat Neurosci. 2015 May;18(5):647-56. doi: 10.1038/nn.3995. Epub 2015 Apr 6.PMID: 25849986 

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.PMID: 25849900 

 Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Nat Commun. 2015 Feb 18;6:6244. doi: 10.1038/ncomms7244.PMID: 25692716 

A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Polstein LR, Gersbach CA. Nat Chem Biol. 2015 Mar;11(3):198-200. doi: 10.1038/nchembio.1753. Epub 2015 Feb 9.PMID: 25664691 

Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells.
Diekman BO, Thakore PI, O'Connor SK, Willard VP, Brunger JM, Christoforou N, Leong KW, Gersbach CA, Guilak F. Tissue Eng Part A. 2015 Apr;21(7-8):1261-74. doi: 10.1089/ten.TEA.2014.0240. Epub 2015 Jan 23.PMID: 25517798 

Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain.
Kabadi AM, Thakore PI, Vockley CM, Ousterout DG, Gibson TM, Guilak F, Reddy TE, Gersbach CA. ACS Synth Biol. 2015 Jun 19;4(6):689-99. doi: 10.1021/sb500322u. Epub 2014 Dec 31.PMID: 25494287 

2014

Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis.
Chakraborty S, Ji H, Chen J, Gersbach CA, Leong KW. Sci Rep. 2014 Dec 10;4:7403. doi: 10.1038/srep07403.PMID: 25492703 

Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, Reddy TE, Gersbach CA. Mol Ther. 2015 Mar;23(3):523-32. doi: 10.1038/mt.2014.234. Epub 2014 Dec 10.PMID: 25492562 

A CRISPR/Cas9-based system for reprogramming cell lineage specification.
Chakraborty S, Ji H, Kabadi AM, Gersbach CA, Christoforou N, Leong KW. Stem Cell Reports. 2014 Dec 9;3(6):940-7. doi: 10.1016/j.stemcr.2014.09.013. Epub 2014 Oct 23.PMID: 25448066 

Special issue on engineered DNA-binding proteins.
Kabadi AM, Gersbach CA. ACS Synth Biol. 2014 Oct 17;3(10):702-3. doi: 10.1021/sb500325e.PMID: 25324185 

Genome engineering: the next genomic revolution.
Gersbach CA. Nat Methods. 2014 Oct;11(10):1009-11. doi: 10.1038/nmeth.3113.PMID: 25264777 

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. Nucleic Acids Res. 2014 Oct 29;42(19):e147. doi: 10.1093/nar/gku749. Epub 2014 Aug 13.PMID: 25122746 

Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression.
Kabadi AM, Gersbach CA. Methods. 2014 Sep;69(2):188-97. doi: 10.1016/j.ymeth.2014.06.014. Epub 2014 Jul 8.PMID: 25010559 

Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine.
Gersbach CA, Perez-Pinera P. Expert Opin Ther Targets. 2014 Aug;18(8):835-9. doi: 10.1517/14728222.2014.913572. Epub 2014 Jun 11.PMID: 24917359 

Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies.
Gersbach CA, Gaj T, Barbas CF 3rd. Acc Chem Res. 2014 Aug 19;47(8):2309-18. doi: 10.1021/ar500039w. Epub 2014 May 30.PMID: 24877793 

Tissue-engineered cartilage with inducible and tunable immunomodulatory properties.
Glass KA, Link JM, Brunger JM, Moutos FT, Gersbach CA, Guilak F. Biomaterials. 2014 Jul;35(22):5921-31. doi: 10.1016/j.biomaterials.2014.03.073. Epub 2014 Apr 22.PMID: 24767790 

Light-inducible gene regulation with engineered zinc finger proteins.
Polstein LR, Gersbach CA. Methods Mol Biol. 2014;1148:89-107. doi: 10.1007/978-1-4939-0470-9_7.PMID: 24718797 

Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage.
Brunger JM, Huynh NP, Guenther CM, Perez-Pinera P, Moutos FT, Sanchez-Adams J, Gersbach CA, Guilak F. Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):E798-806. doi: 10.1073/pnas.1321744111. Epub 2014 Feb 18.PMID: 24550481 

2013

RNA-guided gene activation by CRISPR-Cas9-based transcription factors.
Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. Nat Methods. 2013 Oct;10(10):973-6. doi: 10.1038/nmeth.2600. Epub 2013 Jul 25.PMID: 23892895

Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.
Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, Fedrigo O, Mouly V, Tremblay JP, Gersbach CA. Mol Ther. 2013 Sep;21(9):1718-26. doi: 10.1038/mt.2013.111. Epub 2013 Jun 4.PMID: 23732986 

How vinculin regulates force transmission.
Dumbauld DW, Lee TT, Singh A, Scrimgeour J, Gersbach CA, Zamir EA, Fu J, Chen CS, Curtis JE, Craig SW, García AJ. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9788-93. doi: 10.1073/pnas.1216209110. Epub 2013 May 28.PMID: 23716647 

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.
Gaj T, Gersbach CA, Barbas CF 3rd. Trends Biotechnol. 2013 Jul;31(7):397-405. doi: 10.1016/j.tibtech.2013.04.004. Epub 2013 May 9.PMID: 23664777 

The role of single-cell analyses in understanding cell lineage commitment.
Gibson TM, Gersbach CA. Biotechnol J. 2013 Apr;8(4):397-407. doi: 10.1002/biot.201200201. Epub 2013 Mar 21.PMID: 23520130 

Synergistic and tunable human gene activation by combinations of synthetic transcription factors.
Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA. Nat Methods. 2013 Mar;10(3):239-42. doi: 10.1038/nmeth.2361. Epub 2013 Feb 3.PMID: 23377379 

Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases.
Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, Chuah M, Cornetta K, Davies KE, Dickson JG, Duchateau P, Flotte TR, Gaudet D, Gersbach CA, Gilbert R, Glorioso J, Herzog RW, High KA, Huang W, Huard J, Joung JK, Liu D, Liu D, Lochmüller H, Lustig L, Martens J, Massie B, Mavilio F, Mendell JR, Nathwani A, Ponder K, Porteus M, Puymirat J, Samulski J, Takeda S, Thrasher A, VandenDriessche T, Wei Y, Wilson JM, Wilton SD, Wolfe JH, Gao G. Mol Ther. 2013 Feb;21(2):266-8. doi: 10.1038/mt.2013.4.PMID: 23369965 

Highly active zinc-finger nucleases by extended modular assembly.
Bhakta MS, Henry IM, Ousterout DG, Das KT, Lockwood SH, Meckler JF, Wallen MC, Zykovich A, Yu Y, Leo H, Xu L, Gersbach CA, Segal DJ. Genome Res. 2013 Mar;23(3):530-8. doi: 10.1101/gr.143693.112. Epub 2012 Dec 5.PMID: 23222846 

2012

Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors.
Polstein LR, Gersbach CA. J Am Chem Soc. 2012 Oct 10;134(40):16480-3. doi: 10.1021/ja3065667. Epub 2012 Sep 27.PMID: 22963237 

Advances in targeted genome editing.
Perez-Pinera P, Ousterout DG, Gersbach CA. Curr Opin Chem Biol. 2012 Aug;16(3-4):268-77. doi: 10.1016/j.cbpa.2012.06.007. Epub 2012 Jul 20.PMID: 22819644 

Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases.
Perez-Pinera P, Ousterout DG, Brown MT, Gersbach CA. Nucleic Acids Res. 2012 Apr;40(8):3741-52. doi: 10.1093/nar/gkr1214. Epub 2011 Dec 14.PMID: 22169954 

2011

Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase.Gersbach CA, Gaj T, Gordley RM, Mercer AC, Barbas CF 3rd. Nucleic Acids Res. 2011 Sep 1;39(17):7868-78. doi: 10.1093/nar/gkr421. Epub 2011 Jun 7.PMID: 21653554 

Structure-guided reprogramming of serine recombinase DNA sequence specificity.
Gaj T, Mercer AC, Gersbach CA, Gordley RM, Barbas CF 3rd. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):498-503. doi: 10.1073/pnas.1014214108. Epub 2010 Dec 27.PMID: 21187418 

2010

Directed evolution of recombinase specificity by split gene reassembly.
Gersbach CA, Gaj T, Gordley RM, Barbas CF 3rd. Nucleic Acids Res. 2010 Jul;38(12):4198-206. doi: 10.1093/nar/gkq125. Epub 2010 Mar 1.PMID: 20194120 

2009

Synthesis of programmable integrases.
Gordley RM, Gersbach CA, Barbas CF 3rd. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5053-8. doi: 10.1073/pnas.0812502106. Epub 2009 Mar 12.PMID: 19282480 

2007

Biomaterial-mediated retroviral gene transfer using self-assembled monolayers.
Gersbach CA, Coyer SR, Le Doux JM, García AJ. Biomaterials. 2007 Dec;28(34):5121-7. doi: 10.1016/j.biomaterials.2007.07.047. Epub 2007 Aug 14.PMID: 17698189 

Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2.
Pregizer S, Barski A, Gersbach CA, García AJ, Frenkel B. J Cell Biochem. 2007 Dec 15;102(6):1458-71. doi: 10.1002/jcb.21366.PMID: 17486635

Genetic engineering for skeletal regenerative medicine.
Gersbach CA, Phillips JE, García AJ. Annu Rev Biomed Eng. 2007;9:87-119. doi: 10.1146/annurev.bioeng.9.060906.151949.PMID: 17425467 Review.

In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts.
Gersbach CA, Guldberg RE, García AJ. J Cell Biochem. 2007 Apr 1;100(5):1324-36. doi: 10.1002/jcb.21118.PMID: 17131362

Virus-based gene therapy strategies for bone regeneration.
Phillips JE, Gersbach CA, García AJ. Biomaterials. 2007 Jan;28(2):211-29. doi: 10.1016/j.biomaterials.2006.07.032. Epub 2006 Aug 22.PMID: 16928397 Review.

2006

Inducible regulation of Runx2-stimulated osteogenesis.
Gersbach CA, Le Doux JM, Guldberg RE, García AJ. Gene Ther. 2006 Jun;13(11):873-82. doi: 10.1038/sj.gt.3302725.PMID: 16496016

Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation.
Phillips JE, Gersbach CA, Wojtowicz AM, García AJ. J Cell Sci. 2006 Feb 1;119(Pt 3):581-91. doi: 10.1242/jcs.02758.PMID: 16443755

2005

Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries.
Lan MA, Gersbach CA, Michael KE, Keselowsky BG, García AJ. Biomaterials. 2005 Aug;26(22):4523-31. doi: 10.1016/j.biomaterials.2004.11.028. Epub 2004 Dec 25.PMID: 15722121

2004

Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro.
Gersbach CA, Byers BA, Pavlath GK, Guldberg RE, García AJ. Biotechnol Bioeng. 2004 Nov 5;88(3):369-78. doi: 10.1002/bit.20251.PMID: 15486943

Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype.
Gersbach CA, Byers BA, Pavlath GK, García AJ. Exp Cell Res. 2004 Nov 1;300(2):406-17. doi: 10.1016/j.yexcr.2004.07.031.PMID: 15475005

2003

Addressing cell-sourcing limitations with gene therapy.
García AJ, Guldberg RE, Byers BA, Gersbach CA, Phillips JE. IEEE Eng Med Biol Mag. 2003 Sep-Oct;22(5):65-70. doi: 10.1109/memb.2003.1256274.PMID: 14699938